Targeted therapies in breast cancer: are heart and vessels also being targeted?

Abstract:

:The concept of 'targeted' therapies implies that such drugs only act on cells that specifically express the particular target, therefore giving rise to a low incidence of side effects. However, targeted therapies currently approved for the treatment of breast cancer have demonstrated a relatively high incidence of cardiovascular events. The anti-HER2 agents trastuzumab and lapatinib may cause left ventricular dysfunction or even congestive heart failure. Bevacizumab, an antiangiogenic drug, has been shown to increase the risk of hypertension, cardiovascular dysfunction and thromboembolic events. In addition, several anti-human epidermal growth factor receptor 2 (HER2) and antiangiogenic agents plus their combinations are currently being developed and evaluated for the treatment of breast cancer. In this review, we aim to assess the incidence of cardiac adverse events associated with targeted therapies designed to block HER2 and angiogenic pathways.

journal_name

Breast Cancer Res

authors

Criscitiello C,Metzger-Filho O,Saini KS,de Castro G Jr,Diaz M,La Gerche A,de Azambuja E,Piccart-Gebhart MJ

doi

10.1186/bcr3142

subject

Has Abstract

pub_date

2012-06-19 00:00:00

pages

209

issue

3

eissn

1465-5411

issn

1465-542X

pii

bcr3142

journal_volume

14

pub_type

杂志文章,评审
  • BRCA1 and BRCA2 mutations in a population-based study of male breast cancer.

    abstract:BACKGROUND:The contribution of BRCA1 and BRCA2 to the incidence of male breast cancer (MBC) in the United Kingdom is not known, and the importance of these genes in the increased risk of female breast cancer associated with a family history of breast cancer in a male first-degree relative is unclear. METHODS:We have c...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr419

    authors: Basham VM,Lipscombe JM,Ward JM,Gayther SA,Ponder BA,Easton DF,Pharoah PD

    更新日期:2002-01-01 00:00:00

  • Prognostic stromal gene signatures in breast cancer.

    abstract:INTRODUCTION:Global gene expression analysis of tumor samples has been a valuable tool to subgroup tumors and has the potential to be of prognostic and predictive value. However, tumors are heterogeneous, and homogenates will consist of several different cell types. This study was designed to obtain more refined expres...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0530-2

    authors: Winslow S,Leandersson K,Edsjö A,Larsson C

    更新日期:2015-02-21 00:00:00

  • Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study.

    abstract:INTRODUCTION:Menopausal hormone therapy has been reported to increase the risk of certain subtypes of breast cancer and to be associated with a favorable survival. These associations could either be due to an increased mammographic surveillance or to a biological effect. We assessed these associations in a Swedish coho...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究

    doi:10.1186/bcr2145

    authors: Rosenberg LU,Granath F,Dickman PW,Einarsdóttir K,Wedrén S,Persson I,Hall P

    更新日期:2008-01-01 00:00:00

  • Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.

    abstract:INTRODUCTION:Sustained HER2 signaling at the cell surface is an oncogenic mechanism in a significant proportion of breast cancers. While clinically effective therapies targeting HER2 such as mAbs and tyrosine kinase inhibitors exist, tumors overexpressing HER2 eventually progress despite treatment. Thus, abrogation of ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3204

    authors: Ren XR,Wei J,Lei G,Wang J,Lu J,Xia W,Spector N,Barak LS,Clay TM,Osada T,Hamilton E,Blackwell K,Hobeika AC,Morse MA,Lyerly HK,Chen W

    更新日期:2012-06-07 00:00:00

  • Not all false positive diagnoses are equal: On the prognostic implications of false-positive diagnoses made in breast MRI versus in mammography / digital tomosynthesis screening.

    abstract:BACKGROUND:Breast magnetic resonance imaging (MRI) has been reported to frequently result in false-positive diagnoses, limiting its positive predictive value (PPV). However, for PPV calculation, all nonmalignant tissue changes are equally considered false-positive, although the respective prognostic importance, and thu...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-018-0937-7

    authors: Kuhl CK,Keulers A,Strobel K,Schneider H,Gaisa N,Schrading S

    更新日期:2018-02-09 00:00:00

  • Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment.

    abstract:BACKGROUND:Breast adipocytes play important roles in both the development and function of mammary epithelial cells. Therefore, carcinoma-adipose stromal cell (ASC) interactions have been considered pivotal in supporting tumor growth in breast cancer. In addition, it has been demonstrated that the biological features of...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-017-0863-0

    authors: Sakurai M,Miki Y,Takagi K,Suzuki T,Ishida T,Ohuchi N,Sasano H

    更新日期:2017-06-19 00:00:00

  • JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.

    abstract:INTRODUCTION:Breast cancer is a worldwide health problem and the leading cause of cancer death among females. We previously identified Jumonji domain containing 2A (JMJD2A) as a critical mediator of breast cancer proliferation, migration and invasion. We now report that JMJD2A could promote breast cancer progression th...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3667

    authors: Li LL,Xue AM,Li BX,Shen YW,Li YH,Luo CL,Zhang MC,Jiang JQ,Xu ZD,Xie JH,Zhao ZQ

    更新日期:2014-05-30 00:00:00

  • Trastuzumab emtansine: mechanisms of action and drug resistance.

    abstract::Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that is effective and generally well tolerated when administered as a single agent to treat advanced breast cancer. Efficacy has now been demonstrated in randomized trials as first line, second line, and later than the second line treatment of advanced breast...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr3621

    authors: Barok M,Joensuu H,Isola J

    更新日期:2014-03-05 00:00:00

  • Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.

    abstract:INTRODUCTION:Metastasis is the main cause of breast cancer morbidity and mortality. Processes that allow for tumor cell migration and invasion are important therapeutic targets. Here we demonstrate that receptor-interacting protein kinase 2 (RIP2), a kinase known to be involved in inflammatory processes, also has novel...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3629

    authors: Singel SM,Batten K,Cornelius C,Jia G,Fasciani G,Barron SL,Wright WE,Shay JW

    更新日期:2014-03-19 00:00:00

  • Dendritic cell defects in patients with cancer: mechanisms and significance.

    abstract::Dendritic cells (DCs) are a complex network of antigen-presenting cells that have an essential role in the modulation of primary immunity. There has been increasing evidence that DCs isolated from patients with malignancy demonstrate functional deficiencies that inhibit the capacity to mount an effective anti-tumor re...

    journal_title:Breast cancer research : BCR

    pub_type: 评论,杂志文章

    doi:10.1186/bcr1375

    authors: Lenahan C,Avigan D

    更新日期:2006-01-01 00:00:00

  • Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer.

    abstract:INTRODUCTION:Despite advances in early detection and adjuvant targeted therapies, breast cancer is still the second most common cause of cancer mortality among women. Tumor recurrence is one of the major contributors to breast cancer mortality. However, the mechanisms underlying this process are not completely understo...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0649-1

    authors: Holdman XB,Welte T,Rajapakshe K,Pond A,Coarfa C,Mo Q,Huang S,Hilsenbeck SG,Edwards DP,Zhang X,Rosen JM

    更新日期:2015-11-18 00:00:00

  • Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions.

    abstract::Adjuvant hormonal therapy for postmenopausal women with early stage breast cancer has become far more complex over the past several years. This commentary reviews the current status of the five major trials evaluating the use of the aromatase inhibitors in the adjuvant setting. The data currently available suggest tha...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1347

    authors: Ligibel JA,Winer EP

    更新日期:2005-01-01 00:00:00

  • Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.

    abstract:BACKGROUND:Fragments of collagen type I containing the epitope AHDGGR (CTX) are generated during bone resorption. The aspartyl-glycine (DG) site within CTX is synthesised in the L-aspartyl peptide (alphaL) form, but converts to the age-modified forms L-isoaspartyl peptide (betaL) and D-aspartyl peptide (alphaD) over ti...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr607

    authors: Cloos PA,Christgau S,Lyubimova N,Body JJ,Qvist P,Christiansen C

    更新日期:2003-01-01 00:00:00

  • Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.

    abstract:INTRODUCTION:The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) is a multidisciplinary, collaborative framework for the investigation of familial breast cancer. Based in Australia, the primary aim of kConFab is to facilitate high-quality research by amassing a large and comp...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1377

    authors: Mann GJ,Thorne H,Balleine RL,Butow PN,Clarke CL,Edkins E,Evans GM,Fereday S,Haan E,Gattas M,Giles GG,Goldblatt J,Hopper JL,Kirk J,Leary JA,Lindeman G,Niedermayr E,Phillips KA,Picken S,Pupo GM,Saunders C,Scott CL

    更新日期:2006-01-01 00:00:00

  • Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.

    abstract:INTRODUCTION:PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α) somatic mutations are the most common genetic alteration in breast cancer (BC). Their prognostic value and that of the phosphatidylinositol 3-kinase (PI3K) pathway in BC remains only partly defined. The effect of PIK3CA mutations ...

    journal_title:Breast cancer research : BCR

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1186/bcr3683

    authors: López-Knowles E,Segal CV,Gao Q,Garcia-Murillas I,Turner NC,Smith I,Martin LA,Dowsett M

    更新日期:2014-06-30 00:00:00

  • Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts.

    abstract:INTRODUCTION:Rapamycin, an inhibitor of the serine/threonine kinase target of rapamycin, induces G1 arrest and/or apoptosis. Although rapamycin and its analogues are attractive candidates for cancer therapy, their sensitivities with respect to growth inhibition differ markedly among various cancer cells. Using human br...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1344

    authors: Kasukabe T,Okabe-Kado J,Kato N,Sassa T,Honma Y

    更新日期:2005-01-01 00:00:00

  • The clinical and functional significance of c-Met in breast cancer: a review.

    abstract::c-Met is a receptor tyrosine kinase that upon binding of its ligand, hepatocyte growth factor (HGF), activates downstream pathways with diverse cellular functions that are important in organ development and cancer progression. Anomalous c-Met signalling has been described in a variety of cancer types, and the receptor...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/s13058-015-0547-6

    authors: Ho-Yen CM,Jones JL,Kermorgant S

    更新日期:2015-04-08 00:00:00

  • Activating mutations and senescence secretome: new insights into HER2 activation, drug sensitivity and metastatic progression.

    abstract::HER2 amplification and overexpression is observed in approximately 20% of breast cancers and is strongly associated with poor prognosis and therapeutic responsiveness to HER2 targeted agents. A recent study by Bose and colleagues suggests that another subset of breast cancer patients without HER2 amplification but wit...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3406

    authors: Acharyya S

    更新日期:2013-04-23 00:00:00

  • Assessing breast cancer cell lines as tumour models by comparison of mRNA expression profiles.

    abstract:INTRODUCTION:Breast cancer researchers use cell lines to model myriad phenomena ranging from DNA repair to cancer stem cell phenotypes. Though appropriate, and even requisite, for many studies, the suitability of cell lines as tumour models has come into question owing to possibilities of tissue culture artefacts and c...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0613-0

    authors: Vincent KM,Findlay SD,Postovit LM

    更新日期:2015-08-20 00:00:00

  • Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.

    abstract:INTRODUCTION:Reliable predictive and prognostic markers for routine diagnostic purposes are needed for breast cancer patients treated with neoadjuvant chemotherapy. We evaluated protein biomarkers in a cohort of 116 participants of the GeparDuo study on anthracycline/taxane-based neoadjuvant chemotherapy for operable b...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1186/bcr2363

    authors: Darb-Esfahani S,Loibl S,Müller BM,Roller M,Denkert C,Komor M,Schlüns K,Blohmer JU,Budczies J,Gerber B,Noske A,du Bois A,Weichert W,Jackisch C,Dietel M,Richter K,Kaufmann M,von Minckwitz G

    更新日期:2009-01-01 00:00:00

  • Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stage.

    abstract::Estrogen-mediated proliferation is fundamental to normal mammary gland development. Recent studies have demonstrated that amphiregulin is a critical paracrine regulator of estrogen action during ductal morphogenesis. These studies implicate a critical role for amphiregulin in mammary stem cell differentiation as well ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1740

    authors: LaMarca HL,Rosen JM

    更新日期:2007-01-01 00:00:00

  • Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.

    abstract:INTRODUCTION:Bisphosphonates have become standard therapy for the treatment of skeletal complications related to breast cancer. Although their therapeutic effects mainly result from an inhibition of osteoclastic bone resorption, in vitro data indicate that they also act directly on breast cancer cells, inhibiting proli...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1845

    authors: Journé F,Kheddoumi N,Chaboteaux C,Duvillier H,Laurent G,Body JJ

    更新日期:2008-01-01 00:00:00

  • Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.

    abstract:INTRODUCTION:Triple-negative breast cancer (TNBC), a subtype of breast cancer with negative expressions of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2), is frequently diagnosed in younger women and has poor prognosis for disease-free and overall survival. Due to the lack...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3575

    authors: Chen YJ,Yeh MH,Yu MC,Wei YL,Chen WS,Chen JY,Shih CY,Tu CY,Chen CH,Hsia TC,Chien PH,Liu SH,Yu YL,Huang WC

    更新日期:2013-11-12 00:00:00

  • Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3.

    abstract:INTRODUCTION:Involution of the mammary gland is a complex process of controlled apoptosis and tissue remodelling. The aim of the project was to identify genes that are specifically involved in this process. METHODS:We used Affymetrix oligonucleotide microarrays to perform a detailed transcript analysis on the mechanis...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr753

    authors: Stein T,Morris JS,Davies CR,Weber-Hall SJ,Duffy MA,Heath VJ,Bell AK,Ferrier RK,Sandilands GP,Gusterson BA

    更新日期:2004-01-01 00:00:00

  • Independent and joint cross-sectional associations of statin and metformin use with mammographic breast density.

    abstract:BACKGROUND:Well-tolerated and commonly used medications are increasingly assessed for reducing breast cancer risk. These include metformin and statins, both linked to reduced hormone availability and cell proliferation or growth and sometimes prescribed concurrently. We investigated independent and joint associations o...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01336-0

    authors: Lee Argov EJ,Acheampong T,Terry MB,Rodriguez CB,Agovino M,Wei Y,Athilat S,Tehranifar P

    更新日期:2020-09-15 00:00:00

  • Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.

    abstract:INTRODUCTION:Bisphosphonates are inhibitors of osteoclast-mediated tumor-stimulated osteolysis, and they have become standard therapy for the management of bone metastases from breast cancer. These drugs can also directly induce growth inhibition and apoptosis of osteotropic cancer cells, including estrogen receptor-po...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1363

    authors: Journe F,Chaboteaux C,Magne N,Duvillier H,Laurent G,Body JJ

    更新日期:2006-01-01 00:00:00

  • Plasma levels of leptin and mammographic density among postmenopausal women: a cross-sectional study.

    abstract:INTRODUCTION:Obesity has been linked to increased risk of breast cancer in postmenopausal women. Increased peripheral production of estrogens has been regarded as the main cause for this association, but other features of increased body fat mass may also play a part. Leptin is a protein produced mainly by adipose tissu...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1603

    authors: Stuedal A,Ursin G,Veierød MB,Bremnes Y,Reseland JE,Drevon CA,Gram IT

    更新日期:2006-01-01 00:00:00

  • Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study.

    abstract:INTRODUCTION:Primary breast cancer involving four or more axillary lymph nodes carries a poor prognosis. We hypothesized that use of an immunohistochemical biomarker scoring system could allow for identification of variable risk subgroups. METHODS:Patients with four or more positive axillary nodes were identified from...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,随机对照试验

    doi:10.1186/bcr1847

    authors: Crabb SJ,Bajdik CD,Leung S,Speers CH,Kennecke H,Huntsman DG,Gelmon KA

    更新日期:2008-01-01 00:00:00

  • The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis.

    abstract:INTRODUCTION:Matrix metalloproteinase (MMP)-2 is very active at degrading extracellular matrix. It is under the influence of an activator, membrane type 1 MMP (MMP-14), and the tissue inhibitor of metalloproteases (TIMP)-2. We hypothesized that the individual expression of these three markers or their balance may help ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1503

    authors: Têtu B,Brisson J,Wang CS,Lapointe H,Beaudry G,Blanchette C,Trudel D

    更新日期:2006-01-01 00:00:00

  • Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.

    abstract:INTRODUCTION:Breast tumor kinase (Brk/protein tyrosine kinase 6 (PTK6)) is a nonreceptor, soluble tyrosine kinase overexpressed in the majority of breast tumors. Previous work has placed Brk downstream of epidermal growth factor receptor (ErbB) activation and upstream of extracellular signal-regulated kinase 5 (ERK5) a...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2622

    authors: Castro NE,Lange CA

    更新日期:2010-01-01 00:00:00